Voyager Therapeutics, Inc. Increase (Decrease) in Contract with Customer, Liability
Voyager Therapeutics, Inc. (VYGR) reported Increase (Decrease) in Contract with Customer, Liability of -$1.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06
- Voyager Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$151.00K.
- Voyager Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$1.20M.
- Voyager Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$10.46M.
- Voyager Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$11.07M.
- Voyager Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$28.81M.
- Voyager Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$44.84M, a 576.33% decline from fiscal 2023.
- Voyager Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $9.41M, a 60.33% decline from fiscal 2022.
- Voyager Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was $23.73M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.35M 10-Q · filed 2026-08-06 | -$11.80M derived: sum of 3 quarters · filed 2026-08-06 | -$22.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.20M 10-Q · filed 2026-05-07 | -$11.65M derived: sum of 2 quarters · filed 2026-05-07 | -$22.73M derived: sum of 3 quarters · filed 2026-05-07 | -$25.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$10.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$21.53M derived: sum of 2 quarters · filed 2026-03-09 | -$24.27M derived: sum of 3 quarters · filed 2026-08-06 | -$28.81M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$11.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$13.81M derived: sum of 2 quarters · filed 2026-08-06 | -$18.35M 10-Q · filed 2025-11-10 | -$22.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$7.27M 10-Q · filed 2026-08-06 | -$11.66M derived: sum of 3 quarters · filed 2026-08-06 | -$16.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$4.54M 10-Q · filed 2026-05-07 | -$8.93M derived: sum of 2 quarters · filed 2026-05-07 | -$14.13M derived: sum of 3 quarters · filed 2026-05-07 | -$38.74M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$4.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$9.59M derived: sum of 2 quarters · filed 2026-03-09 | -$34.20M derived: sum of 3 quarters · filed 2026-03-09 | -$44.84M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$5.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$29.82M derived: sum of 2 quarters · filed 2025-11-10 | -$40.46M 10-Q · filed 2025-11-10 | -$47.30M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | -$24.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$35.25M 10-Q · filed 2025-08-06 | -$42.10M derived: sum of 3 quarters · filed 2026-03-09 | -$43.06M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | -$10.64M 10-Q · filed 2025-05-06 | -$17.49M derived: sum of 2 quarters · filed 2026-03-09 | -$18.45M derived: sum of 3 quarters · filed 2026-03-09 | -$19.95M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | -$6.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$7.81M derived: sum of 2 quarters · filed 2026-03-09 | -$9.31M derived: sum of 3 quarters · filed 2026-03-09 | $9.41M 10-K · filed 2026-03-09 |
| 2023-09-30 | -$962.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.46M derived: sum of 2 quarters · filed 2024-11-12 | $16.26M 10-Q · filed 2024-11-12 | $18.07M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | -$1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $17.22M 10-Q · filed 2024-08-06 | $19.03M derived: sum of 3 quarters · filed 2025-03-11 | -$11.83M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $18.73M 10-Q · filed 2024-05-13 | $20.53M derived: sum of 2 quarters · filed 2025-03-11 | -$10.33M derived: sum of 3 quarters · filed 2025-03-11 | -$10.89M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$29.06M derived: sum of 2 quarters · filed 2025-03-11 | -$29.62M derived: sum of 3 quarters · filed 2025-03-11 | $23.73M 10-K · filed 2025-03-11 |
| 2022-09-30 | -$30.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$31.42M derived: sum of 2 quarters · filed 2023-11-06 | $21.93M 10-Q · filed 2023-11-06 | $24.84M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$560.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $52.79M 10-Q · filed 2023-08-03 | $55.71M derived: sum of 3 quarters · filed 2024-02-28 | $55.16M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $53.35M 10-Q · filed 2023-05-09 | $56.27M derived: sum of 2 quarters · filed 2024-02-28 | $55.72M derived: sum of 3 quarters · filed 2024-02-28 | $55.39M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.37M derived: sum of 2 quarters · filed 2024-02-28 | $2.04M derived: sum of 3 quarters · filed 2024-02-28 | -$1.72M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$549.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$881.00K derived: sum of 2 quarters · filed 2022-11-08 | -$4.64M 10-Q · filed 2022-11-08 | -$6.50M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | -$332.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$4.09M 10-Q · filed 2022-08-04 | -$5.95M derived: sum of 3 quarters · filed 2023-03-07 | -$127.04M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | -$3.76M 10-Q · filed 2022-05-04 | -$5.61M derived: sum of 2 quarters · filed 2023-03-07 | -$126.71M derived: sum of 3 quarters · filed 2023-03-07 | -$146.09M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | -$1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$122.95M derived: sum of 2 quarters · filed 2023-03-07 | -$142.33M derived: sum of 3 quarters · filed 2023-03-07 | -$150.68M 10-K · filed 2023-03-07 |
| 2020-09-30 | -$121.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$140.48M derived: sum of 2 quarters · filed 2021-11-02 | -$148.82M 10-Q · filed 2021-11-02 | -$165.96M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | -$19.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$27.73M 10-Q · filed 2021-08-09 | -$44.87M derived: sum of 3 quarters · filed 2022-03-08 | -$52.96M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | -$8.34M 10-Q · filed 2021-05-10 | -$25.48M derived: sum of 2 quarters · filed 2022-03-08 | -$33.58M derived: sum of 3 quarters · filed 2022-03-08 | -$76.12M derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | -$17.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$25.23M derived: sum of 2 quarters · filed 2022-03-08 | -$67.78M derived: sum of 3 quarters · filed 2022-03-08 | $80.83M 10-K · filed 2022-03-08 |
| 2019-09-30 | -$8.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$50.64M derived: sum of 2 quarters · filed 2020-11-09 | $97.97M 10-Q · filed 2020-11-09 | $95.97M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$42.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $106.06M 10-Q · filed 2020-08-10 | $104.06M derived: sum of 3 quarters · filed 2021-02-25 | $101.96M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $148.61M 10-Q · filed 2020-05-06 | $146.60M derived: sum of 2 quarters · filed 2021-02-25 | $144.51M derived: sum of 3 quarters · filed 2021-02-25 | $141.93M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$4.10M derived: sum of 2 quarters · filed 2021-02-25 | -$6.68M derived: sum of 3 quarters · filed 2021-02-25 | $61.38M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$4.67M derived: sum of 2 quarters · filed 2019-11-06 | $63.39M 10-Q · filed 2019-11-06 | $57.04M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-06-30 | -$2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $65.48M 10-Q · filed 2019-08-09 | $59.14M derived: sum of 3 quarters · filed 2020-03-03 | |
| 2018-03-31 | $68.06M 10-Q · filed 2019-05-07 | $61.71M derived: sum of 2 quarters · filed 2020-03-03 | ||
| 2017-12-31 | -$6.34M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | -$10.13M 10-K · filed 2020-03-03 | ||
| 2017-09-30 | -$3.79M 10-Q · filed 2018-11-07 | |||
| 2016-12-31 | -$14.58M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |